IDH1 and IDH2 Mutations in Gliomas

Yan, Hai, Parsons, D. Williams, Jin, Genglin, McLendon, Roger, Rasheed, B. Ahmed, Yuan, Weishi, Kos, Ivan, Batinic-Haberle, Ines +10 more·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0808710

Cited by (1,012)

Items 201–300 of 1,012

  1. Coupling Krebs cycle metabolites to signalling in immunity and cancer
    Ryan, Dylan G., Murphy, Michael P., Frezza, Christian, Prag, Hiran A., Chouchani, Edward T., O’Neill, Luke A., Mills, Evanna L. · 2018 · Nature Metabolism
  2. Glioblastoma: clinical presentation, diagnosis, and management
    Chris McKinnon, Meera Nandhabalan, Scott A Murray, Puneet Plaha · 2021 · BMJ
  3. Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging
    Ken Chang, Harrison Xiao Bai, Hao Zhou, Chang Su, Wenya Linda Bi, Ena Agbodza, Vasileios K. Kavouridis, Joeky T. Senders, Alessandro Boaro, Andrew L. Beers et al. · 2017 · Clinical Cancer Research
  4. SDH mutations in cancer
    Bardella, Chiara, Pollard, Patrick J., Tomlinson, Ian · 2011 · Biochimica et Biophysica Acta (BBA) - Bioenergetics
  5. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
    Saman Abbas, Sanne Lugthart, François G. Kavelaars, Anita M. Schelen, Jasper E. Koenders, Annelieke Zeilemaker, Wim J. L. van Putten, Anita W. Rijneveld, Bob Löwenberg, Peter J.M. Valk · 2010 · Blood
  6. The implications of IDH mutations for cancer development and therapy
    Christopher J. Pirozzi, Hai Yan · 2021 · Nature Reviews Clinical Oncology
  7. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
    Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge, Michael A. Vogelbaum, Anna K. Nowak, Marc Sanson, Alba Ariela Brandes, Paul M. Clément, Jean Français Baurain, Warren P. Mason et al. · 2017 · The Lancet
  8. Cancer metabolism: current perspectives and future directions
    Muñoz-Pinedo, C, El Mjiyad, N, Ricci, J-E · 2012 · Cell Death & Disease
  9. Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression
    Yekaterina A. Miroshnikova, Janna K. Mouw, James Matthew Barnes, Michael W. Pickup, Johnathan N. Lakins, Youngmi Kim, Khadjia A. Lobo, Anders I. Persson, Gerald F. Reis, Tracy Richmond McKnight et al. · 2016 · Nature Cell Biology
  10. Identifying emerging topics in science and technology
    Henry G. Small, Kevin W. Boyack, Richard Klavans · 2014 · Research Policy
  11. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
    Martin J. van den Bent, Hendrikus Jan Dubbink, Yannick Marie, Alba Ariela Brandes, MARTIN J.B. TAPHOORN, Pieter Wesseling, Marc Frénay, Cees C. Tijssen, Denis A. Lacombe, Ahmed Idbaïh et al. · 2010 · Clinical Cancer Research
  12. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
    Long, Georgina V., Fung, Carina, Menzies, Alexander M., Pupo, Gulietta M., Carlino, Matteo S., Hyman, Jessica, Shahheydari, Hamideh, Tembe, Varsha, Thompson, John F., Saw, Robyn P. et al. · 2014 · Nature Communications
  13. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis
    Dania Daye, Kathryn E. Wellen · 2012 · Seminars in Cell and Developmental Biology
  14. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system
    Simon Gritsch, Tracy T. Batchelor, L. Nicolas Gonzalez Castro · 2021 · Cancer
  15. IDH mutations in glioma and acute myeloid leukemia
    Lenny Dang, Shengfang Jin, Shin-San Michael Su · 2010 · Trends in Molecular Medicine
  16. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
    Sequist, L.V., Heist, R.S., Shaw, A.T., Fidias, P., Rosovsky, R., Temel, J.S., Lennes, I.T., Digumarthy, S., Waltman, B.A., Bast, E. et al. · 2011 · Annals of Oncology
  17. Deep learning with convolutional neural network in radiology
    Yasaka, Koichiro, Akai, Hiroyuki, Kunimatsu, Akira, Kiryu, Shigeru, Abe, Osamu · 2018 · Japanese Journal of Radiology
  18. Emerging treatment strategies for glioblastoma multiforme
    Steven K. Carlsson, Shaun P. Brothers, Claes Wahlestedt · 2014 · EMBO Molecular Medicine
  19. Mitochondria and Epigenetics – Crosstalk in Homeostasis and Stress
    Olli Matilainen, Pedro M. Quirós, Johan H. Auwerx · 2017 · Trends in Cell Biology
  20. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
    Olar, Adriana, Wani, Khalida M., Alfaro-Munoz, Kristin D., Heathcock, Lindsey E., van Thuijl, Hinke F., Gilbert, Mark R., Armstrong, Terri S., Sulman, Erik P., Cahill, Daniel P., Vera-Bolanos, Elizabeth et al. · 2015 · Acta Neuropathologica
  21. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors
    Beatrice S. Melin, Jill S. Barnholtz‐Sloan, Margaret Wrensch, Christoffer Johansen, Dora Il’yasova, Ben Kinnersley, Quinn T. Ostrom, Karim Labrèche, Yanwen Chen, Georgina Armstrong et al. · 2017 · Nature Genetics
  22. Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
    Junfeng Bi, Sudhir Chowdhry, Sihan Wu, Wenjing Zhang, Kenta Masui, Paul S. Mischel · 2019 · Nature reviews. Cancer
  23. Pediatric low-grade glioma in the era of molecular diagnostics
    Scott T. Ryall, Uri Y. Tabori, Cynthia E Hawkins · 2020 · Acta Neuropathologica Communications
  24. EMT Factors and Metabolic Pathways in Cancer
    Ilias Georgakopoulos‐Soares, Dionysios V. Chartoumpekis, Venetsana E. Kyriazopoulou, Apostolos Zaravinos · 2020 · Frontiers in Oncology
  25. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers
    Andrey Korshunov, Marina Vladimirovna Ryzhova, Volker Hovestadt, Sebastian Bender, Dominik Sturm, David Capper, Jochen Meyer, Daniel Schrimpf, Marcel Kool, Paul A. Northcott et al. · 2015 · Acta Neuropathologica
  26. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Roger Stupp, Joerg‐Christian Tonn, Michael Brada, George E. Pentheroudakis · 2010 · Annals of Oncology
  27. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data
    Wei Yang, Nicole M. Warrington, Sara J. Taylor, Paula Whitmire, Eduardo Carrasco, Kyle Singleton, Ningying Wu, Justin Durla Lathia, Michael E. Berens, Albert H. Kim et al. · 2019 · Science Translational Medicine
  28. Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas
    Malzkorn, Bastian, Wolter, Marietta, Liesenberg, Franziska, Grzendowski, Michael, Stühler, Kai, Meyer, Helmut E., Reifenberger, Guido · 2010 · Brain Pathology
  29. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
    Reuss, David E., Mamatjan, Yasin, Schrimpf, Daniel, Capper, David, Hovestadt, Volker, Kratz, Annekathrin, Sahm, Felix, Koelsche, Christian, Korshunov, Andrey, Olar, Adriana et al. · 2015 · Acta Neuropathologica
  30. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles
    Walter W. Chen, Leonora Balaj, Linda M. Liau, Michael L. Samuels, Steve K. Kotsopoulos, Casey A. Maguire, Lori LoGuidice, Horacio Soto, Matthew C. Garrett, Lin Dan Zhu et al. · 2013 · Molecular Therapy — Nucleic Acids
  31. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
    Elanor N. Wainwright, Paola Scaffidi · 2017 · Trends in Cancer
  32. Metabolism of [U‐ <sup>13</sup> C]glucose in human brain tumors <i>in vivo</i>
    Maher, Elizabeth A., Marin‐Valencia, Isaac, Bachoo, Robert M., Mashimo, Tomoyuki, Raisanen, Jack, Hatanpaa, Kimmo J., Jindal, Ashish, Jeffrey, F. Mark, Choi, Changho, Madden, Christopher et al. · 2012 · NMR in Biomedicine
  33. Biological Role and Therapeutic Potential of IDH Mutations in Cancer
    Matthew S. Waitkus, Bill H. Diplas, Hai Yan · 2018 · Cancer Cell
  34. IDH1 and IDH2 Mutations in Gliomas
    Joon H. Uhm · 2009 · Yearbook of Neurology and Neurosurgery
  35. Metabolic Codependencies in the Tumor Microenvironment
    Prasenjit Dey, Alec C. Kimmelman, Ronald Anthony DePinho · 2021 · Cancer Discovery
  36. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis
    Ying Qing, Lei Dong, Lei Gao, Chenying Li, Yangchan Li, Li Han, Emily A. Prince, Brandon Tan, Xiaolan Deng, Collin Wetzel et al. · 2021 · Molecular Cell
  37. Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma
    Zeju Li, Yuanyuan Wang, Jinhua Yu, Yi Guo, Wei Cao · 2017 · Scientific Reports
  38. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression
    Raoxu Wang, Bowen Li, Sin Man Lam, Guanghou Shui · 2019 · Journal of genetics and genomics/Journal of Genetics and Genomics
  39. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
    Anna Maria Jankowska, Hideki Makishima, Ramon Velasquez Tiu, Hadrian Szpurka, Yun Huang, Fabı́ola Traina, Valeria Visconte, Yuka Sugimoto, Courtney J. Prince, Christine L. O’Keefe et al. · 2011 · Blood
  40. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells
    Jin‐Qiang Chen, José Russo · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  41. Targeting mitochondrial metabolism for precision medicine in cancer
    Lourdes Sainero‐Alcolado, Judit Liaño-Pons, María Victoria Ruiz-Pérez, Marie Arsenian‐Henriksson · 2022 · Cell Death and Differentiation
  42. Metabolic reprogramming and epithelial‐to‐mesenchymal transition in cancer
    Marco Sciacovelli, Christian Frezza · 2017 · FEBS Journal
  43. Glioblastoma multiforme: State of the art and future therapeutics
    DavidH. Harter, TaylorA Wilson, Matthias A. Karajannis · 2014 · Surgical Neurology International
  44. Reactive Oxygen Species in Cancer Stem Cells
    Xiaoke Shi, Yan Zhang, Junheng Zheng, Jingxuan Pan · 2012 · Antioxidants and Redox Signaling
  45. Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
    Omar Ibrahim Abdel-Wahab, Taghi Manshouri, Jay L. Patel, Kelly Harris, JinJuan Yao, Cyrus V. Hedvat, Adriana Heguy, Carlos Bueso-Ramos, Hagop M. Kantarjian, Ross L. Levine et al. · 2010 · Cancer Research
  46. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
    Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth Anne Maher, Macarena I. de la Fuente, Matthias Holdhoff, Gregory Michael Cote, Howard A. Burris, Filip Jankú, Robert J. Young et al. · 2020 · Journal of Clinical Oncology
  47. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
    Wojciech Szopa, Thomas A. Burley, Gabriela Krämer-Marek, Wojciech Kaspera · 2017 · BioMed Research International
  48. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
    William H. Tomaszewski, Luis A Sanchez-Perez, Thomas Frank Gajewski, John Howard Sampson · 2019 · Clinical Cancer Research
  49. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
    Margaret J. Dougherty, Mariarita Santi, Marcia S. Brose, Changqing Ma, Adam Cain Resnick, Angela Jae Sievert, Phillip B. Storm, Jaclyn A. Biegel · 2010 · Neuro-Oncology
  50. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
    Pope, Whitney B., Prins, Robert M., Albert Thomas, M., Nagarajan, Rajakumar, Yen, Katharine E., Bittinger, Mark A., Salamon, Noriko, Chou, Arthur P., Yong, William H., Soto, Horacio et al. · 2012 · Journal of Neuro-Oncology
  51. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
    Ayalew Tefferi, Terra L. Lasho, Omar Ibrahim Abdel-Wahab, Paola Guglielmelli, Jay L. Patel, Domenica Caramazza, Lisa Pieri, Christy M. Finke, Outi Kilpivaara, Martha Wadleigh et al. · 2010 · Leukemia
  52. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
    Philipp Kickingereder, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, Benedikt Wiestler · 2015 · Scientific Reports
  53. Spatiotemporal Evolution of the Primary Glioblastoma Genome
    Jinkuk Kim, In‐Hee Lee, Hee Jin Cho, Chul‐Kee Park, Yang-Soon Jung, Yanghee Kim, So Hee Nam, Byung Sup Kim, Mark D. Johnson, Doo‐Sik Kong et al. · 2015 · Cancer Cell
  54. BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
    Dora C. Dias-Santagata, Quynh Lam, Kathy Vernovsky, Natalie Vena, Jochen K. Lennerz, Darrell R. Borger, Tracy T. Batchelor, Keith Lloyd Ligon, Anthony John Iafrate, Azra Hadi Ligon et al. · 2011 · PLoS ONE
  55. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
    Eskil Eskilsson, Gro Vatne Røsland, Gergely Morten Solecki, Qianghu Wang, Patrick N. Harter, Grazia Graziani, Roel G.W. Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletić · 2017 · Neuro-Oncology
  56. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
    Horbinski, Craig, Berger, Tamar, Packer, Roger J., Wen, Patrick Y. · 2022 · Nature Reviews Neurology
  57. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Shota Tanaka, David N. Louis, William T. Curry, Tracy T. Batchelor, Jörg Dietrich · 2012 · Nature Reviews Clinical Oncology
  58. The DNA methylation landscape in cancer
    Ksenia Skvortsova, Clare Stirzaker, Phillippa C. Taberlay · 2019 · Essays in Biochemistry
  59. Current trends in the surgical management and treatment of adult glioblastoma.
    Richard M Young, Aria M. Jamshidi, Gregory Davis, Jonathan H. Sherman · 2015 · Europe PMC (PubMed Central)
  60. NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐functional network with GLI1 and p53
    Marie Zbinden, Arnaud Duquet, Aiala Lorente‐Trigos, Sandra-Nadia Ngwabyt Bikeye, Isabel Borges, Ariel Ruiz i Altaba · 2010 · The EMBO Journal
  61. New aspects of the Warburg effect in cancer cell biology
    Steven J. Bensinger, Heather R. Christofk · 2012 · Seminars in Cell and Developmental Biology
  62. Glioblastoma at the crossroads: current understanding and future therapeutic horizons
    Shilpi Singh, Devanjan Dey, Debashis Barik, Iteeshree Mohapatra, Stefan Kim, Mayur Sharma, Sujata Prasad, Peize Wang, Amar Ranjan Singh, Gatikrushna Singh · 2025 · Signal Transduction and Targeted Therapy
  63. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
    Laukka, Tuomas, Mariani, Christopher J., Ihantola, Tuukka, Cao, John Z., Hokkanen, Juho, Kaelin, William G., Godley, Lucy A., Koivunen, Peppi · 2016 · Journal of Biological Chemistry
  64. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
    Aoki, Kosuke, Nakamura, Hideo, Suzuki, Hiromichi, Matsuo, Keitaro, Kataoka, Keisuke, Shimamura, Teppei, Motomura, Kazuya, Ohka, Fumiharu, Shiina, Satoshi, Yamamoto, Takashi et al. · 2018 · Neuro-Oncology
  65. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
    Tathiane Maistro Malta, Camila Ferreira de Souza, Thaís S. Sabedot, Tiago C. Silva, Maritza S. Mosella, Steven N. Kalkanis, James Snyder, Ana Valeria B. Castro, Houtan Noushmehr · 2017 · Neuro-Oncology
  66. The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
    Fonnet E. Bleeker, Nadia A. Atai, Simona Lamba, Ard Jonker, Denise Rijkeboer, Klazien S. Bosch, Wikky Tigchelaar, Dirk Troost, William Peter Vandertop, Alberto Bardelli et al. · 2010 · Acta Neuropathologica
  67. Role of mitochondrial dysfunction in cancer progression
    Chia‐Chi Hsu, Ling‐Ming Tseng, Hsin‐Chen Lee · 2016 · Experimental Biology and Medicine
  68. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas
    Tamar R. Berger, Patrick Yung Wen, Melanie Lang‐Orsini, Ugonma Nnenna Chukwueke · 2022 · JAMA Oncology
  69. Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
    Rafael L. Bejar, Ross L. Levine, Benjamin L. Ebert · 2011 · Journal of Clinical Oncology
  70. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
    Camilla Krakstad, Martha Chekenya · 2010 · Molecular Cancer
  71. Mitochondrial DNA variation and cancer
    Kopinski, Piotr K., Singh, Larry N., Zhang, Shiping, Lott, Marie T., Wallace, Douglas C. · 2021 · Nature reviews. Cancer
  72. Hypoxia-driven pathways in bone development, regeneration and disease
    Christa Maes, Geert Carmeliet, Ernestina Schipani · 2012 · Nature Reviews Rheumatology
  73. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma
    Chris Jones, Suzanne J. Baker · 2014 · Nature reviews. Cancer
  74. Cancer-associated IDH mutations: biomarker and therapeutic opportunities
    Yen, K E, Bittinger, M A, Su, S M, Fantin, V R · 2010 · Oncogene
  75. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function
    Sasaki, Masato, Knobbe, Christiane B., Itsumi, Momoe, Elia, Andrew J., Harris, Isaac S., Chio, Iok In Christine, Cairns, Rob A., McCracken, Susan, Wakeham, Andrew, Haight, Jillian et al. · 2012 · Genes &amp; Development
  76. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
    Songtao Qi, Lei Yu, Si Gui, Ding YanQing, Han HuiXia, Zhang Xue-lin, Wu Lanxiao, Yao Fei · 2011 · Cancer Science
  77. Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain
    Lionel M.L. Chow, Raelene Endersby, Xiaoyan Zhu, Sherri L. Rankin, Chunxu Qu, Junyuan Zhang, Alberto Broniscer, David W. Ellison, Suzanne J. Baker · 2011 · Cancer Cell
  78. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions
    Sameer Agnihotri, Gelareh Mohammed Zadeh · 2015 · Neuro-Oncology
  79. Low-grade gliomas in adults
    Nader Sanai, Susan Chang, Mitchel Stuart Berger · 2011 · Journal of neurosurgery
  80. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
    Sabine Hombach‐Klonisch, Maryam Mehrpour, Shahla Shojaei, Craig Henry Harlos, Marshall W. Pitz, Ahmed Hamaï, Krzysztof Siemianowicz, Wirginia Likus, Emilia Wiecheć, Brian D. Toyota et al. · 2017 · Pharmacology & Therapeutics
  81. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas
    Adam M. Fontebasso, Jeremy Schwartzentruber, Dong-Anh Khuong-Quang, Xiao-Yang Liu, Dominik Sturm, Andrey Korshunov, David Jones, Hendrik Witt, Marcel Kool, Steffen Albrecht et al. · 2013 · Acta Neuropathologica
  82. Glioma: experimental models and reality
    Krissie Lenting, Roel G.W. Verhaak, Mark ter Laan, Pieter Wesseling, William P. J. Leenders · 2017 · Acta Neuropathologica
  83. Marked for death: Targeting epigenetic changes in cancer
    Pfister, Sophia Xiao, Ashworth, Alan · 2017 · Nature Reviews Drug Discovery
  84. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis
    Philippe Métellus, Béma Coulibaly, Carole Colin, A. Maues de Paula, Alexandre Vasiljevic, David Taïeb, Anne Barlier, Blandine Boisselier, Karima Mokhtari, Xiao Wei Wang et al. · 2010 · Acta Neuropathologica
  85. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
    Manfred Westphal, Katrin Lamszus · 2011 · Nature reviews. Neuroscience
  86. Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
    Anthony Richard Green, Philip A. Beer · 2010 · New England Journal of Medicine
  87. Advances in Brain Tumor Surgery for Glioblastoma in Adults
    Montserrat A. Lara-Velazquez, Rawan Al‐kharboosh, Stéphanie Jeanneret, Carla A. Vazquez-Ramos, Deependra Mahato, Daryoush Tavanaiepour, Gazanfar Rahmathulla, Alfredo Quiñones‐Hinojosa · 2017 · Brain Sciences
  88. Isocitrate dehydrogenase mutations in gliomas
    Matthew S. Waitkus, Bill H. Diplas, Hai Yan · 2015 · Neuro-Oncology
  89. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
    Siân Jones, Meng Li, Donald Williams Parsons, Xiaosong Zhang, Jelle Wesseling, Petra Kristel, Marjanka K. Schmidt, Sanford D. Markowitz, Hai Yan, Darell D. Bigner et al. · 2011 · Human Mutation
  90. Metabolic genes in cancer: Their roles in tumor progression and clinical implications
    Eiji Furuta, Hiroshi Okuda, Aya Kobayashi, Kounosuke Watabe · 2010 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  91. In vivo models of primary brain tumors: pitfalls and perspectives
    Peter Csaba Huszthy, Inderjit Daphu, Simone P. Niclou, Daniel Stieber, Janice M. Nigro, Per Øystein Sakariassen, Hrvoje Miletić, Frits Alan Thorsen, Rolf Bjerkvig · 2012 · Neuro-Oncology
  92. Molecular diagnostics of gliomas: state of the art
    Markus J. Riemenschneider, Judith W. M. Jeuken, Pieter Wesseling, Guido Reifenberger · 2010 · Acta Neuropathologica
  93. A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities
    Juliana A. Ronchi, Tiago R. Figueira, Felipe Gustavo Ravagnani, Helena C.F. Oliveira, Aníbal Eugênio Vercesi, Roger Frigerio Castilho · 2013 · Free Radical Biology and Medicine
  94. Clinical trial links oncolytic immunoactivation to survival in glioblastoma
    Alexander Lee Ling, Isaac H. Solomon, Ana Montalvo Landivar, Hiroshi Nakashima, Jared K. Woods, Andres Santos, Nafisa Masud, Geoffrey G. Fell, Xiaokui Molly Mo, Ayse Selen Yilmaz et al. · 2023 · Nature
  95. Next-generation sequencing to guide cancer therapy
    Jeffrey Gagan, Eliezer M. Van Allen · 2015 · Genome Medicine
  96. Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation status
    Bardella, Chiara, El‐Bahrawy, Mona, Frizzell, Norma, Adam, Julie, Ternette, Nicola, Hatipoglu, Emine, Howarth, Kimberley, O'Flaherty, Linda, Roberts, Ian, Turner, Gareth et al. · 2011 · The Journal of Pathology
  97. Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms
    Federica Sotgia, Ubaldo Martinez‐Outschoorn, Anthony Howell, Richard G. Pestell, Stephanos Pavlides, Michael P. Lisanti · 2011 · Annual Review of Pathology Mechanisms of Disease
  98. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism
    Grassian, Alexandra R., Parker, Seth J., Davidson, Shawn M., Divakaruni, Ajit S., Green, Courtney R., Zhang, Xiamei, Slocum, Kelly L., Pu, Minying, Lin, Fallon, Vickers, Chad et al. · 2014 · Cancer Research
  99. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
    Marianne Labussière, Ahmed Idbaïh, X.-W. Wang, Yannick Marie, Blandine Boisselier, C. Falet, Sophie Paris, Julien Laffaire, C. Carpentier, Emmanuelle Crinière et al. · 2010 · Neurology
  100. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
    David Reuß, Annekathrin Kratz, Felix Sahm, David Capper, Daniel Schrimpf, Christian Koelsche, Volker Hovestadt, Melanie Bewerunge‐Hudler, David Jones, Jens Schittenhelm et al. · 2015 · Acta Neuropathologica